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Abstract
Objectives: Patients with inherited bleeding disorders are at high risk of bleeding following oral surgery and pres-
ent challenges to the oral surgeons. Aim of this study was to report our experience in dental extraction in patients 
exhibiting Haemophilia A and B between 2007 and 2012.
Patient and Methods: 58 dental extractions in 15 patients during 19 interventions were performed. Replacement 
therapy with recombinant and plasma-derived factor VIII and IX was applied systematically in combination with 
antifibrinolytic treatment and local haemostatic measures. The following data were recorded: type of surgery, 
applied local haemostatic measures, general substitution, systemic antifibrinolytic agents and occurrence of post-
operative bleeding complications.
Results: Two patients presented postoperative bleeding. One had secondary bleeding requiring additional injec-
tion of factor concentrates. The other one presented epistaxis which was managed conservatively with a nasal 
tamponade.
Conclusions: Excellent haemostasis is achievable after dental extractions in patients with Haemophilia A and B 
by following a protocol using defined pre- and postoperative doses of factor concentrates in combination with 
haemostatic measures.
Key words: Antifibrinolytic treatment, dental extraction, Haemophilia, inherited bleeding disorders, local hae-
mostatic measures.
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Introduction
Haemophilia is a common hereditary bleeding disorder. 
More than 400,000 people are affected worldwide (1). 
The X-linked recessive chromosomal bleeding disorder 
is caused by a variety of mutations in the factor VIII 
(Haemophilia A) or factor IX (Haemophilia B) gene. 
As a result men are expressing the disease, meanwhile 
women are typically asymptomatic carriers. One third 
of all cases of Haemophilia are the result of spontane-
ous mutations. Two thirds have a prior family history.
Haemophilia A is the most common form of this disor-
der. Approximately 1:5,000 males are affected. In com-
parison Haemophilia B is less often, 1:30,000 males are 
affected (2). Haemophilia is summarized as follows: 
mild when plasma activity is between 6 and 40 % of 
normal; moderate if it ranges between 1-5 % and severe 
if it is <1 % (3). 
Patients with Haemophilia are at high risk of intra- and 
postoperative bleeding when oral surgery has to be per-
formed. Therefore management of patients with heredi-
tary bleeding disorders requires close cooperation be-
tween oral surgeons and a comprehensive Haemophilia 
treatment center. The use of clotting factor replacement 
therapy for all invasive surgical interventions is required 
(4,5). Successful treatment protocols are described in the 
current literature using systemic treatment, antifibrino-
lytic agents and local haemostatic measures (6,7).
Purpose of the presented study was to report our experi-
ence in dental extractions and to evaluate the efficacy of 
a systematic protocol involving systemic treatment com-
bined with local haemostatic techniques to prevent bleed-
ing after dental extraction in patients with Haemophilia.
Patient and Methods
The study includes results of 58 extractions in 15 pa-
tients. General anesthesia was performed if necessary. 
Articain with Adrenaline 1:100,000 (Ultracain D-S 
forte, Sanofi-Aventis, Paris, France) was used for lo-
cal anesthesia. Recombinant and plasma-derived factor 
Haemophilia A Haemophilia B
Type of surgery Desired factor  level 
in %
Duration (days) Desired factor level 
in %
Duration (days)
Major surgery
Pre-op 80–100 60–80
Post-op 60–80 1–3 40–60 1–3
40–60 4–6 30–50 4–6
30–50 7–14 20–40 7–14
Minor Surgery
Pre-op 50–80 50–80
Post-op 30–80 1–5 30–80 1–5
Table 1. Plasma factor level and duration of the replacement therapy needed for surgical interventions in patients with Haemophilia (23).
VIII and IX were applied for systemic treatment. The 
selected factor replacement therapy protocols are given 
in table 1. The following formulas were applied for cal-
culating the factor dose:
Dosage (units) = body weight (kg) × desired factor VIII 
rise (IU/dL or % of normal) × 0.5 and Dosage (units) 
= body weight (kg) × desired factor IX rise (IU/dL or 
% of normal).
The replacement with doses of native plasma derived 
factor VIII was initiated in four patients exhibiting se-
vere Haemophilia A and two patients with mild Haemo-
philia A. Doses of recombinant factor VIII were used in 
two patients with severe Haemophilia A and two patients 
with mild Haemophilia A. In one patient with mild Hae-
mophilia A, treatment with Desmopressin (DDAVP) in-
creased satisfying the factor VIII level without factor 
concentrate injection. Two weeks earlier a prior testing 
had been carried out with Minirin to assess the level of 
patient response. 
Doses of native plasma derived factor IX were used in 
three patients exhibiting severe Haemophila B and one 
patient with moderate Haemophilia B. 
In all cases injection was administered half-hour be-
fore surgery. The clotting factor level was planned to 
increase from 50-100 IU/dL of normal preoperatively. 
The postoperative factor trough levels were aimed to 
remain above 30 % (Table 1). Further doses of clotting 
factor were applied in the next days. 
Tranexamic acid (Cyklokapron, Meda Pharma, Bad 
Homburg, Germany) was used systematically in 16 in-
terventions. It was administered intravenous and orally 
at a dose of 20 mg/kg of body weight every eight hours 
for seven days. Due to cardiovascular contraindications 
it was not used in three cases.
Furthermore gauzes saturated with tranexamic acid 
were applied in all patients during the first three days 
after surgery. Patients with contraindications for sys-
temic antifibrinolytic agents received tranexamic acid 
only topical.
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Table 2. Distribution of patients included in this report: type of surgery, anesthesia, substitution and local haemostatic measures.
Patient Age Sex Pathology Basal 
factor
level, 
%
Type 
of surgery 
Anesthesia General 
substituti
on
Systemic 
anti-
fibrinolytic 
agents
Local
haemostatic
measures 
B.B. 8 M H.A <1 84,85,54,64 G.A. SDH 
Intersero 
tranexamic 
acid 
collagen vlies; 
suture 
D.K. 51 M H.A <1 14,12,s37 L.A. SDH 
Intersero 
tranexamic 
acid 
collagen vlies, 
suture 
H.A. 61 M H.A 25 17,s36,s37 L.A. Haemate 
P
contra-
indications 
collagen vlie, 
suture 
M.P. 17 M H.A 10 12,22,55,36 G.A. Helixate tranexamic 
acid 
collagen vlies, 
suture 
M.V. 14 M H.A <1 36 L.A. Helixate tranexamic 
acid 
collagen vlies, 
suture 
D.H. 28 M H.B <1 s17,s25,31 L.A. Berinin tranexamic 
acid 
collagen vlies, 
suture 
E.L. 74 M H.B 4 11,21,22, 
23,31,32, 
41,42 
L.A. Berinin contra-
indications 
collagen 
vlies,suture 
E.L. 74 M H.B 4 12,13,44, 
45,48 
L.A. Berinin contra-
indications 
collagen 
vlies,suture 
MA.K. 4 M H.A <1 54,75,84 G.A. Octanine tranexamic 
acid 
collagen vlies, 
suture 
D.K. 51 M H.A <1 12,11,21,25 L.A. SDH 
Intersero 
tranexamic 
acid 
oxycellulose, 
suture 
M.V. 11 M H.A <1 54,55,74 G.A. Helixate tranexamic 
acid 
oxycellulose, 
suture 
T.R. 21 M H.A <1 s18,s28, 
s38,s48
G.A. SDH 
Intersero 
tranexamic 
acid 
oxycellulose, 
suture 
C.S. 22 M H.A 15 s17 L.A. Kogenate 
FS 
tranexamic 
acid 
collagen vlies, 
suture, fibrin 
glue
C.U. 32 M H.A <1 36 L.A. Helixate tranexamic 
acid 
collagen vlies, 
suture, fibrin 
glue
E.H. 20 M H.A 10 s18,s28, 
s38,s48
L.A. SDH 
Intersero 
tranexamic 
acid 
collagen vlies, 
suture, fibrin 
glue
S.W. 21 F H.B <1 s38,s48 L.A. Octanine tranexamic 
acid 
collagen vlies, 
fibrin glue, 
suture 
D.K. 50 M H.A <1 22,26,27 L.A. SDH 
Intersero 
tranexamic 
acid 
collagen vlies, 
suture, fibrin 
glue,
compressive 
splints
M.L. 47 M H.A 24 26 L.A. Minirin tranexamic 
acid 
collagen vlies, 
suture, 
compressive 
splints
J.B. 7 M H.B <1 61 G.A. Immunine tranexamic 
acid 
suture 
?
Local haemostatic measures were applied in all cases 
according to surgeon preference and practice pattern 
(Table 2). Collagen vlies (Lyostypt, B. Braun Melsun-
gen, Melsungen, Germany), oxycellulose (Tabotamp, 
Ethicon Johnson&Johnson, New Brunswick, USA), fi-
brin glue (Tissucol Duo S, Baxter, Munich, Germany) 
resorbable suture (Vicryl, Ethicon Johnson&Johnson, 
New Brunswick, USA) were used.
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Antibiotics were prescribed if clinically necessary. 
Postoperative pain was controlled by adequate doses of 
Paracetamol.
Results
Distribution of patients is given in table 2. Overall 58 
dental extractions in 15 patients aged 4 to 74 years, 
mean age 32 ± 22.5 years (mean ±SD), 14 male (93%), 
one female (7%) during 19 interventions over a peri-
od of 6 years (2007-2012) were performed. 11 patients 
(73%) were affected by Haemophilia A (six from the se-
vere and five from the moderate form) and four patients 
(27%) by Haemophilia B (three from the severe and one 
from the mild form). 
General anesthesia was necessary in six cases and 
local anesthesia in 13 cases. Secondary bleeding oc-
curred in two patients with mild Haemophilia A. First 
patient, who had had all four wisdom teeth removed 
in local anesthesia, bled from the nose on the seventh 
postoperative day which was controlled with a nasal 
tamponade left in situ for two days. Second patient, 
who had had three teeth extracted, bled on the fifth day 
after surgery. To control bleeding this case required 
the additional use of clotting factor replacement ther-
apy and repeated compression with gauzes saturated 
with tranexamic acid. No general complications were 
noted. All patients were hospitalized for a mean period 
of six days. 
Discussion
Patients with Haemophilia are at high risk of secondary 
bleeding following oral surgery. Close cooperation be-
tween haematologists and oral surgeons is necessary to 
prevent excessive haemorrhage. International guidelines 
strongly recommend the use of clotting factor replace-
ment therapy for all invasive surgical interventions (5). 
The World Federation of Haemophilia (WFH) advises 
the use of factor concentrates to cryoprecipitate or fresh 
frozen plasma for the replacement therapy in patients 
with Haemophilia. Factor VIII and IX concentrates 
may be divided into two categories, recombinant and 
plasma-derived factor. There are no statements from 
the WFH for a preference for recombinant over plasma-
derived concentrates. The level of factor required for 
surgical procedures in haemophiliacs is given in table 
1. In this study we used native plasma derived concen-
trates in 10 cases and recombinant concentrates in four 
cases. One unit of infused recombinant factor VIII per 
kilogram of body weight should lead to a rise of plasma 
factor VIII level of approximately 2% in patients with 
Haemophilia A and in absence of an inhibitor. The half-
life of factor VIII is approximately 8–12 h. On the other 
side, one unit of infused plasma-derived concentrates 
of factor IX per kilogram of body weight will raise the 
plasma factor IX activity by approximately 1% in pa-
tients with Haemophilia B in absence of an inhibitor 
(8). In contrast to the native plasma-derived factor, the 
recombinant factor IX has a lower recovery. One unit 
of infused factor IX per kg body weight should raise 
the plasma factor IX level approximately 0.8% in adults 
and 0.7 % in children (9). The half-life of factor IX is 
approximately 18–24 h (10).
The conventional replacement therapy is not effective in 
patients with antibodies to factor VIII and IX. Approxi-
mately 8 to 20% of the patients with severe Haemophil-
ia A and 2.5 to 16% of those with severe Haemophilia B 
are affected (11). A variety of genetic and immunologic 
factors are responsible in inhibitor development (12-16). 
However an activated prothrombin complex concen-
trate or a recombinant activated factor VII concentrate 
can be used to this patients (17).
Factor replacement therapy carries a risk of trans-
mission of viruses or new pathogens and may lead 
to develop inhibitors. Therefore reducing the number 
of patients and times requiring factor replacement 
therapy is helpful. DDAVP may be the treatment of 
choice for patients with mild or moderate Haemo-
philia A (18,19). A preoperative single dose of 0.3 µg/
kg of body weight can increase the factor VIII level 
three- to sixfold in good responders (20). It is much 
less expensive than coagulation factor concentrates. 
There is no risk of transmission of infections and no 
risk of immunization. Because of the significant dif-
ferences between individuals, a prior testing of pa-
tient’s response a few weeks before surgery is neces-
sary in these cases. Various reports have described 
dental extractions under DDAVP in patients with 
bleeding disorders (21,22). 
The antifibrinolytic treatment with tranexamic acid 
prevents postoperative bleeding by inhibiting the ac-
tivation of plasminogen to plasmin and promoting the 
clot stability. It is usually given as an oral tablet three 
to four times or by intravenous infusion two to three 
times daily. Tranexamic acid should be prescribed for 
seven days following dental extractions in patients with 
intrinsic bleeding disorders (23). Furthermore various 
reports referred the successful local use of tranexamic 
acid for the reduction of oral bleeding (22,24).
Oral surgeons have to use all techniques to minimise 
the probability of intra- and postoperative bleeding. Lo-
cal haemostatic measures are obligate following dental 
extraction in these patients. Typical agents are sutures 
(22), collagen vlies (21), oxycellulose (25), gelatine (26), 
a fibrin glue (27) and cyanoacrylate (28). In this study 
all mentioned local measures were used according to 
surgeon preference and practice pattern. Furthermore 
the different agents were combined with each other to 
potentiate the haemostatic effect. Wagner et al. com-
pared often used topical haemostatic agents in terms 
of their ability to mediate platelet aggregation, deposi-
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tion and activation in a series of in vitro tests. He pre-
sented an overall activity ranking of the materials used: 
collagen>gelatine>oxidized regenerated cellulose (29). 
In this report we could not note a different efficacy be-
tween the various local haemostatic measures. To pre-
vent late bleeding we used absorbable sutures in order 
to avoid suture removal. For pain control non-steroidal 
anti-inflammatory drugs and aspirin which affect plate-
let function must be avoided. Paracetamol is a safe al-
ternative to prevent postoperative pain.
The current literature reports successful treatment pro-
tocols to prevent bleeding complications following oral 
surgery procedures. The results are similar to our report. 
Frachon et al. evaluated the efficacy of a protocol using 
a general management and combining fibrin glue with 
gelatin packing and compressive splints for the manage-
ment of dental extractions in haemophiliacs. An outcome 
with six instances of postsurgical bleeding during 19 in-
terventions was recorded (22). Frachini et al. analysed 10 
years of experience in managing patients with hereditary 
bleeding disorders in Italy. No specific protocol was used. 
Only 10 bleeding complications (1.9 %) were reported 
when patients are managed by local and systemic meas-
ures (24). Piot et al. reported also good results for dental 
extractions in patients with bleeding disorders. Collagen 
vlies, fibrin suture and primary suture were used in com-
bination. They reported two cases of secondary bleeding 
during 103 dental extractions in 93 patients (21). Zanon 
et al. registered two bleeding complications after dental 
extraction in 75 procedures. Clotting factor concentrates 
to obtain a plasma peak level of 30% were given. Fibrin 
sponges, primary suture and tranexamic acid were used 
for local measures (30). 
In our study sample secondary bleeding occurred in two 
patients surprisingly exhibiting mild form of Haemo-
philia A. This is an indication that postoperative bleed-
ing after oral surgery in patients exhibiting Haemophilia 
is difficult to predict also if defined treatment protocols 
are used. Postoperative monitoring of these patients is 
necessary to prevent excessive haemorrhage.
Conclusion
Considering an individual haemostaseological proto-
col in consultation with a hematologist helps to prevent 
bleeding complications in haemophiliacs undergoing 
dental extractions. Local haemostatic measures have to 
be used whenever possible following a dental extraction 
to reduce the need of factor concentrates. A specialist 
dental service in consultation with a Haemophilia treat-
ment centre should perform these procedures.
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